Xiaoxiao Liang

Xiaoxiao Liang

Auto-generated profile, based on publicly available information

Xiaoxiao Liang

Guangdong Provincial Key Lab of Green Chemical Product Technology, Department of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
XLXiaoxiao Liang
Xiaoxiao Liang
ALAnders Støttrup Larsen
Anders Støttrup Larsen
PHPhilipp Hans
Philipp Hans
DXDi Xu
Di Xu
YLYunxia Li
Yunxia Li
YJYanbin Jiang
Yanbin Jiang
Co-crystals offer a promising strategy to create drug constructs for which the pharmacokinetic properties of an active pharmaceutical ingredient can be improved without compromising its pharmacological effectiveness.

20 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ZZZhenhua Zhao
Zhenhua Zhao
XLXiaoxiao Liang
Xiaoxiao Liang
YSYang Sirui
Yang Sirui
WCWeiyuan Chen
Weiyuan Chen
FZFanting Zhu
Fanting Zhu
QZQiaoxin Zhang
Qiaoxin Zhang
Respiratory tract infections with co-infections involving viruses and bacteria pose major diagnostic challenges. Current methods lack the sensitivity, speed, and multiplexing capacity needed for rapid etiological differentiation. Here, we report a one-pot, amplification-free biosensor integrating CRISPR-Cas12a with surface-enhanced Raman spectroscopy (SERS) for multiplexed detection of SARS-CoV-2, Influenza A virus (FluA), and Haemophilus influenzae (HI). Three SERS-encoded Au nanoprobe pairs are labeled with distinct Raman reporters (4-MBA at 1078 cm-1 for SARS-CoV-2, DTNB at 1325 cm-1 for FluA, and MMC at 1168 cm-1 for HI). The single-stranded DNA (ssDNA) linker is designed to hybridize with probe pairs, inducing aggregation and signal quenching after centrifugation. Target binding activates Cas12a trans-cleavage, preventing probe aggregation and yielding a “turn-on” SERS signal in the supernatant. The platform achieves detection limits of 10 copies/mL for SARS-CoV-2 and FluA, and 100 copies/mL for HI, with a six-order linear range (R2>0.99), high specificity, and reproducibility (RSD<10%). In 50 clinical nasopharyngeal swabs, it shows 100% concordance with qPCR for viral targets and with mass spectrometry for HI. This work demonstrates that CRISPR-SERS integration offers a powerful, multiplexable, and instrument-simplified solution for respiratory infection diagnosis, particularly suitable for point-of-care diagnosis of respiratory co-infections.